Khaled A Tolba
After completing a fellowship in hematology-oncology at the University of Rochester Wilmot Cancer Center, (Rochester, NY) in
June 1999, Dr Khaled A Tolba stayed on faculty as a physician-scientist working in the lab of Dr Joseph D Rosenblatt. Dr Tolba focused
on the development of Herpes simplex virus (HSV) as a therapeutic tool to enhance anti-tumor host immunity. Dr Tolba published his
first manuscript on the subject in 2001 in the journal Blood. Subsequently, he focused on the interface of virus (HSV): host innate
immunity, how different aspects of the host innate immunity, namely activation of the Toll-like receptors (TLR) though virus-derived
pathogen-associated molecular patterns (PAMP), could be exploited to mount an anti-tumor immune response. In parallel, Dr Tolba
continued his clinical work as a medical oncologist focusing on lung and head and neck cancers, his area of clinical expertise. In January
2015 Dr Tolba joined Oregon Health & Science University Knight Cancer Institute, where he manages the lung and head and neck cancer
specialties. His current focus is the development of novel clinical trials.